E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000932 |
E.1.2 | Term | Acute myocarditis |
E.1.2 | System Organ Class | 10007541 - Cardiac disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the effect of CardiolRx on myocardial recovery in patients presenting with acute myocarditis and to demonstrate that administration of CardiolRx in the proposed doses in this patient population is safe. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the effect of CardiolRxTM on myocardial recovery in patients presenting with acute myocarditis |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Males and females 18 years of age or older 2. Diagnosed with acute myocarditis including: a) Clinical criteria (symptoms of chest pain, arrhythmia or shortness of breath, or history of viral-like illness), preferably followed by elevated troponin PLUS b) CMR diagnosis (Lake Louise Criteria) within 10 days prior to randomization OR c) Endomyocardial biopsy (EMB) showing either cellular inflammation and/or immunohistochemistry consistent with inflammation. 3. Male subjects with partners of childbearing potential who have had a vasectomy or are willing to use double barrier contraception methods during the conduct of the study and for 2 months after the last dose of study drug. 4. Women of childbearing potential willing to use an acceptable method of contraception starting with study drug administration and for a minimum of 2 months after study completion. Otherwise, women must be postmenopausal (at least 1 year absence of vaginal bleeding or spotting and confirmed by follicle stimulating hormone [FSH] ≥40 mIU/mL [or ≥ 40 IU/L] if less than 2 y postmenopausal) or be surgically sterile. The following reliable methods of contraception are: parenteral |
|
E.4 | Principal exclusion criteria |
1. Coronary artery disease (CAD) defined as a stenosis greater than 50% in a major epicardial coronary artery 2. Severe valvular heart disease 3. Inability to safely undergo CMR including administration of gadolinium 4. Estimated glomerular filtration rate (eGFR) < 30 ml/min 5. Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 times the upper limit of normal (ULN) or ALT or AST >3x ULN plus bilirubin >2x ULN. 6. Sepsis, defined as documented bacteremia at the time of presentation or other documented active infection. 7. Severe left ventricular (LV) dysfunction - requiring inotropic support, left ventricular assist device (LVAD) or other circulatory assist devices, or urgent need for transplantation 8. Documented biopsy evidence of giant cell or eosinophilic myocarditis |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome of this study is comprised of two primary endpoints, i.e., the difference in the means of each: ECV and GLS, as measured byCMR at 12 weeks post randomization between the active and the placebo groups. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- The secondary outcome of this study is the difference in the means of left-ventricular ejection fraction (LVEF), as measured by CMR at 12 weeks post randomization between the active and the placebo groups.
Other Efficacy Outcomes: - Survival, free from major event (cardiac transplant, left-ventricular assist device (LVAD), hospitalization for heart failure (HF)) through 12 weeks post randomization - Change in CMR parameters from baseline to 12 weeks post randomization: LVEF, ECV, GLS, left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), left atrial endsystolic volume (LAESV), LV mass, late gadolinium enhancement (LGE) imaging, degree of edema - Change in New York Heart Association (NYHA) classification from baseline to 12 weeks post randomization - Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline to 12 weeks post randomization - Time to resolution of clinical symptoms, including chest pain, arrhythmias, shortness of breath - Time to normalization of high sensitivity troponin (hs-troponin), Nterminal pro B-type naturetic peptide (NT-proBNP) and inflammatorymarkers: high sensitivity C reactive protein (hs-CRP), ferritin, tumour necrosis factor alpha (TNF-alpha), interleukin 1-beta (IL-1 beta), interleukin 6 (IL-6), interleukin 10 (IL-10), inerleukin 18 (IL-18) and endothelial markers: soluble vascular cell adhesion molecule-1 (sVCAM- 1), transforming growth factor beta (TGF-beta [beta 1 and beta 2]) - Change in hs-troponin, NT-proBNP and inflammatory markers (hs-CRP, ferritin, TNF-alpha, IL-1 beta, IL-6, IL-10, IL-18 and endothelial markers (sVCAM-1, TGF-beta [beta 1 and beta 2])) from baseline to week 12 post randomization - Time to normalization of electrocardiogram (ECG) abnormalities
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Brazil |
Canada |
Israel |
United States |
France |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 24 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 24 |